Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the 10 oversold small cap stocks to buy now.
As of the April 24 closing, the consensus sentiment around the stock was strongly bullish. It received Buy ratings from all 12 analysts who provided coverage. Moreover, it offers almost 150% upside potential, based on a median 1-year price target of $64.45, making it one of the most attractive small-cap picks.
Pressmaster/Shutterstock.com
The bullish views are also backed by the company’s latest trial outcomes. Back on March 25, Maze Therapeutics Inc. (NASDAQ:MAZE) revealed encouraging results from the Phase 2 HORIZON trial on MZE829, an oral drug inhibiting APOL1, in treating a range of APOL1-induced kidney diseases. 12 weeks of administration of the drug brought about a 35.6% reduction in the mean value of albumin/creatinine ratio in broad AMKD patients, where 50% of patients had a reduction exceeding 30%.
Patients diagnosed with FSGS condition recorded a reduction in mean value by 61.8%, while those suffering from non-diabetic AMKD saw a reduction by 48.6%. There were no severe side effects. Maze intends to move the drug into a pivotal program. Harold Bernstein, President of R&D and Chief Medical Officer, stated that the results demonstrate encouraging proof of concept for the precision medicine treating the cause of AMKD.
Maze Therapeutics Inc. (NASDAQ:MAZE) is a developer of small-molecule precision medicines for the treatment of kidney and metabolic illnesses. The company’s lead programs include MZE829, APOL1, and MZE782. Additionally, it is also involved in the development of MZE001. The company has agreements with various organizations for licensing and commercialization of its products.
While we acknowledge the potential of MAZE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
